Price alert —
Sign in to get a one-time email the moment TMDX crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · TMDX
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.2B | $0.0B | $0.0B | $-0.0B | 4.2% | 7.6% |
| 2025-12-31 | $0.2B | $0.1B | $0.0B | $0.0B | 65.6% | 13.2% |
| 2025-09-30 | $0.1B | $0.0B | $0.0B | $0.1B | 16.9% | 16.2% |
| 2025-06-30 | $0.2B | $0.0B | $0.0B | $0.1B | 22.2% | 23.2% |
| 2025-03-31 | $0.1B | $0.0B | $0.0B | $-0.0B | 17.9% | 19.1% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare TMDX vs peers
Line TMDX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with TMDX
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-05 | 0.30 | 0.61 | -50.9% | -23.2% |
| 2026-02-24 | 0.53 | 0.37 | +41.0% | -4.3% |
| 2025-10-29 | 0.66 | 0.36 | +83.3% | +1.1% |
| 2025-07-30 | 0.92 | 0.43 | +114.8% | +10.5% |
| 2025-05-08 | 0.70 | 0.24 | +190.1% | +19.6% |
| 2025-02-27 | 0.19 | 0.15 | +25.3% | +5.8% |
| 2024-10-28 | 0.12 | 0.32 | -62.3% | -29.9% |
| 2024-07-31 | 0.35 | 0.20 | +71.5% | +6.5% |
| 2024-04-30 | 0.35 | 0.01 | +3268.6% | +24.9% |
| 2024-02-26 | 0.12 | -0.12 | +202.8% | +14.1% |
| 2023-11-06 | 0.07 | -0.13 | +150.8% | +51.2% |
| 2023-08-03 | -0.03 | -0.13 | +77.0% | -8.3% |
| 2023-05-01 | -0.08 | -0.24 | +66.8% | -5.2% |
| 2023-02-22 | -0.21 | -0.27 | +23.6% | +20.6% |
| 2022-11-03 | -0.25 | -0.41 | +39.3% | +24.0% |
| 2022-08-01 | -0.41 | -0.34 | -19.1% | -10.3% |
| 2022-05-03 | -0.38 | -0.39 | +2.3% | +40.3% |
| 2022-02-23 | -0.46 | -0.44 | -4.8% | +30.1% |
| 2021-11-09 | -0.47 | -0.37 | -26.1% | -9.3% |
| 2021-08-05 | -0.39 | -0.29 | -33.1% | +8.5% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| TMDX ★ | $3B | 16.9 | 26.7 | 4.0 | 23.6 | 5.2 | 59.1% | 21.2% | -71.5% | 4.26% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 56.94%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 5,293,331 | 15.32% |
| FMR, LLC | 5,096,243 | 14.75% |
| Vanguard Portfolio Management LLC | 1,919,535 | 5.55% |
| Vanguard Capital Management LLC | 1,478,152 | 4.28% |
| State Street Corporation | 1,319,479 | 3.82% |
| Invesco Ltd. | 1,037,974 | 3.00% |
| UBS AM, a distinct business unit of | 939,523 | 2.72% |
| Nomura Asset Management Internationa | 885,841 | 2.56% |
| Goldman Sachs Group Inc | 866,282 | 2.51% |
| Geode Capital Management, LLC | 839,155 | 2.43% |
Insider activity · 90d
15 buys / 0 sells · ratio 15.0 · Finnhub
- Corcoran Nicholas BUY 17,784
- Corcoran Nicholas BUY 41,558
- Hernandez Gerardo BUY 26,153
- Hernandez Gerardo BUY 31,935
- Hassanein Waleed H BUY 112,984
- Hassanein Waleed H BUY 171,093
- Lovell Stephanie BUY 5,788
- Weill David BUY 15,056
- Basile Edward M BUY 5,788
- Gunderson Thomas J. BUY 6,981
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-14 | 4 | view · |
| 4 | 2026-07-14 | 4 | view · |
| 4 | 2026-07-14 | 4 | view · |
| 4 | 2026-06-17 | 4 | view · |
| 4 | 2026-05-22 | 4 | view · |
| 4 | 2026-05-22 | 4 | view · |
| 4 | 2026-05-22 | 4 | view · |
| 4 | 2026-05-22 | 4 | view · |
| 4 | 2026-05-22 | 4 | view · |
| 4 | 2026-05-22 | 4 | view · |
| 4 | 2026-05-22 | 4 | view · |
| 4 | 2026-05-21 | 4 | view · |
| 8-K | 2026-05-21 | 8-K | view · |
| 10-Q | 2026-05-05 | 10-Q | view · |
| 8-K | 2026-05-05 | 8-K | view · |
| DEF 14A | 2026-04-10 | DEF 14A | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 4 | 2026-03-04 | 4 | view · |
| 8-K | 2026-02-27 | 8-K | view · |
| 10-K | 2026-02-24 | 10-K | view · |
| 8-K | 2026-02-24 | 8-K | view · |
| 4 | 2026-02-20 | 4 | view · |
| 8-K | 2026-02-04 | 8-K | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2025-12-05 | 4 | view · |
| 4 | 2025-12-05 | 4 | view · |
| 4 | 2025-11-26 | 4 | view · |
| 4 | 2025-11-18 | 4 | view · |
| 4 | 2025-10-31 | 4 | view · |
| 10-Q | 2025-10-29 | 10-Q | view · |
| 8-K | 2025-10-29 | 8-K | view · |
| 8-K | 2025-10-06 | 8-K | view · |
| 4 | 2025-08-08 | 4 | view · |
| 4 | 2025-08-05 | 4 | view · |
| 10-Q | 2025-07-30 | 10-Q | view · |
| 8-K | 2025-07-30 | 8-K | view · |
| 4 | 2025-06-10 | 4 | view · |
| 4 | 2025-05-29 | 4 | view · |
| 4 | 2025-05-23 | 4 | view · |
| 4 | 2025-05-23 | 4 | view · |
| 4 | 2025-05-23 | 4 | view · |
| 4 | 2025-05-23 | 4 | view · |
| 4 | 2025-05-23 | 4 | view · |
| 4 | 2025-05-23 | 4 | view · |
| 4 | 2025-05-23 | 4 | view · |
| 8-K | 2025-05-23 | 8-K | view · |
| 4 | 2025-05-13 | 4 | view · |
| 10-Q | 2025-05-08 | 10-Q | view · |
| 8-K | 2025-05-08 | 8-K | view · |
| DEF 14A | 2025-04-10 | DEF 14A | view · |
| 4 | 2025-03-05 | 4 | view · |
| 10-K | 2025-02-27 | 10-K | view · |
| 8-K | 2025-02-27 | 8-K | view · |
| 4 | 2025-02-26 | 4 | view · |
| 4 | 2025-02-26 | 4 | view · |
| 4 | 2025-02-26 | 4 | view · |
| 4 | 2025-02-26 | 4 | view · |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Options picks · TMDX
ITM + OTM ideas from the latest scanLoading…
Congress trades · TMDX
STOCK Act disclosuresLoading…
SEC filings & insiders · TMDX
EDGAR · liveLoading…
Holders · TMDX
Institutions & insider activityLoading…